SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

US Patent Office Issues Notice of Allowance to Perma-Fix Allowing All Claims of Patent Application for Preparation of Microporous Composite Material and Its Applications

ATLANTA, GA and WARSAW, POLAND--(Marketwired - August 27, 2014) - Perma-Fix Medical S.A. (WARSAW: PFM), a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI), and developer of a reliable, cost effective, non-uranium process to produce technetium-99 (Tc-99m), the most widely used medical isotope in the world, today announced that in mid-August 2014, the US Patent Office issued a notice of allowance to Perma-Fix Environmental Services, Inc. allowing all claims in its recent patent application for preparation of its Microporous Composite Material and its derivatives. Perma-Fix Medical has a Patent License Agreement with Perma-Fix Environmental Services, for the production of Tc-99m.

Dr. Louis F. Centofanti, of Perma-Fix Medical, commented, "Issuance of this patent is a major milestone for the company. The U.S. Patent and Trademark Office has granted us protection for our intellectual property to produce Tc-99m. With this patent in hand, we look forward to advancing our cost-effective, non-uranium process, which we believe will reshape the global supply chain of Tc-99m."

The claim of the patent addresses the proprietary resin that Perma-Fix manufactures and includes:

  • Selective separation of Tc-99m pertechnetate from Mo-99
  • Enhanced sorption of Mo with a holding capacity in excess of 60% of the dry weight of the sorbent
  • Sorbent and generator resistant to degradation by gamma and beta radiation and acid environments
  • Sorption of selective isotopes from radioactive waste streams
  • Removal of heavy metals, such as mercury and arsenic, from waste water streams

About Perma-Fix Medical S.A.

Perma-Fix Medical was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at http://www.medical-isotope.com.

About Perma-Fix Environmental Services

Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the Department of Defense ("DOD"), and the commercial nuclear industry. The Company's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.

Please visit us on the World Wide Web at http://www.perma-fix.com.

This press release contains "forward-looking statements" which are based largely on the Company's expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company's control. Forward-looking statements generally are identifiable by use of the words such as "believe", "expects", "intends", "anticipate", "plans to", "estimates", "projects", and similar expressions. Forward-looking statements include, but are not limited to: we look forward to advancing our cost-effective, non-uranium process, which we believe will reshape the global supply chain of Tc-99m. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; continued allowance by the US Patent Office; our ability to apply and market our new technology; protect our intellectual property; and the "Risk Factors" discussed in, and the additional factors referred to under "Special Note Regarding Forward-Looking Statements" of, our 2013 Form 10-K and Forms 10-Q for quarters ended March 31, 2014 and June 30, 2014. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

Contacts:

David K. Waldman
Crescendo Communications Europe S.A.
Tel : +1-212-671-1021

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.